Identification of 6-(piperazin-1-yl)-1,3,5-triazine as a chemical scaffold with broad anti-schistosomal activities.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

1. First In Silico Screening of Insect Molecules for Identification of Novel Anti-Parasitic Compounds.Pharmaceuticals (Basel, Switzerland) · 2022
   Article
2. Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.European journal of medicinal chemistry · 2021
   Article
3. Antiparasitic Properties of Cardiovascular Agents against Human Intravascular ParasitePharmaceuticals (Basel, Switzerland) · 2021
   Article
4. Schistosomiasis Drug Discovery in the Era of Automation and Artificial Intelligence.Frontiers in immunology · 2021
   Review
5. Identification of 6-(piperazin-1-yl)-1,3,5-triazine as a chemical scaffold with broad anti-schistosomal activities.Wellcome open research · 2020
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors at 2 institutions in 4 countries.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as